Ala9.0

Alpha Lipoic Acid

Alpha Lipoic Acid (ALA / R-ALA)

Universal antioxidant that works in both water and fat, supporting blood sugar control, nerve health, and cellular energy.

immunityantioxidantblood sugarneuropathymitochondria
Last reviewed: January 1, 2025
9.0/10
40+ studies
Evidence
moderate
Safety
300-600mg
Dose
4-12 weeks
Time to Effect
R-Alpha Lipoic Acid (R-ALA) — the natural form
Best Form

Alpha Lipoic Acid is a unique antioxidant that's both water and fat-soluble, allowing it to work throughout the body. It's produced naturally but levels decline with age. Research shows benefits for blood sugar regulation, diabetic neuropathy, and as a general antioxidant. Also regenerates other antioxidants like vitamins C and E.

Mechanisms of Action

🛡️
Universal Antioxidant

Works in both water and fat environments

📊
Glucose Uptake

Enhances insulin sensitivity

⚡
Mitochondrial Cofactor

Essential for cellular energy production

Recommended Dose

300-600mg

200mg1200mg

Optimal Timing

  • On empty stomach for best absorption
  • 30-60 minutes before meals

Can be taken without food

Best Form

R-Alpha Lipoic Acid (R-ALA) — the natural form

Alternatives: Racemic ALA (R/S mix), Na-R-ALA (stabilized R-ALA)

R-ALA is the biologically active form. Racemic ALA contains 50% R and 50% S forms. Na-R-ALA is more stable.

Duration

Minimum: 4 weeks

Optimal: 12 weeks

Cycling: Not required

Note: Food reduces absorption. R-ALA form is more bioavailable than racemic ALA. May cause blood sugar to drop if taken with diabetes medications.

Personalized Dosage Calculator

Get a dosage recommendation tailored to your body weight, age, goals, and health profile.

Set up your health profile for personalized recommendations

📊
Blood Sugar Control

Improved glucose metabolism

4-12 weeks
65% of users notice thispositive
🔌
Nerve Health

May reduce neuropathy symptoms

4-8 weeks
55% of users notice thispositive
✨
Antioxidant Boost

Reduced oxidative stress

2-4 weeks
60% of users notice thispositive
ModerateMax safe dose: Up to 1200mg/day used in clinical studies
🔴
Pregnant/nursing

Insufficient data; avoid

🟢
Diabetics

Beneficial but requires monitoring; may need medication adjustment

Who Should NOT Take This

  • Thiamine (B1) deficiency
  • Excessive alcohol use
  • Uncontrolled Diabetes - use with caution

Drug Interactions

Diabetes medicationsmoderate

May enhance blood sugar lowering — monitor closely

Chemotherapymoderate

May interact; consult oncologist

Thyroid medicationsmild

May affect thyroid hormone levels

Possible Side Effects

Nauseauncommon

Tip: Take with small amount of food

Skin rashrare

Tip: Discontinue if occurs

Hypoglycemiauncommon

Tip: Monitor blood sugar if diabetic

Warnings

  • Can cause significant blood sugar drops in diabetics
  • May deplete thiamine (B1) — supplement B1 if using long-term
  • Can have an unpleasant sulfur smell

Top studies from 40+ peer-reviewed papers

meta-analysisn=3771
DOI

Kohandel Gargari O et al. • JAMA network open (2024)

“In this network meta-analysis of randomized clinical trials, topiramate and pregabalin were associated with reduction in headache frequency and intensity.”
Key Findings:
  • Compared with placebo, pregabalin (ratio of means [RoM], 0.38; 95% CI, 0.18-0.79) and topiramate with vitamin D3 (RoM, 0.44; 95% CI, 0.30-0.65) were associated with reduction in migraine frequency.
  • However, no treatments were associated with significant improvements in quality of life or reduction of the duration of migraine attacks.
  • Adverse events were higher with amitriptyline (RR, 3.81; 95% CI, 1.41-10.32), topiramate (RR, 4.34; 95% CI, 1.60-11.75), and valproate (RR, 5.93; 95% CI, 1.93-18.23) compared with placebo.
meta-analysisn=1242
DOI

Hsieh RY et al. • Nutrients (2023)

“The use of ALA to prevent neurological symptoms should be further researched.”
Key Findings:
  • ALA treatment produced favorable results for TSS (a dose-related trend was observed), NDS, and the global satisfaction score.
  • For VAS, VPT, NIS-LL, and NCS results, ALA did not produce favorable results.
  • The use of ALA to prevent neurological symptoms should be further researched.
meta-analysis
DOI

Talandashti MK et al. • Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology (2025)

“The use of certain dietary supplements has resulted in a significant decrease in migraine prophylaxis.”
Key Findings:
  • In adults, compared with placebo, these supplements did not significantly affect other outcomes, and omega-3 supplementation did not yield a statistically significant reduction in any of these outcomes.
  • The use of certain dietary supplements has resulted in a significant decrease in migraine prophylaxis.
  • Further clinical trials of high quality appear to be beneficial.
meta-analysisn=50
DOI

Michaelsen MP et al. • Nutrients (2025)

“This study found no convincing evidence of an effect of any dietary supplements on male infertility.”
Key Findings:
  • This study found no convincing evidence of an effect of any dietary supplements on male infertility.
  • Larger and more well-conducted randomized controlled trials focusing on specific supplements and considering pregnancy outcomes are needed.
  • Further research warranted to confirm findings
meta-analysisn=529
DOI

Sharifi-Zahabi E et al. • International journal for vitamin and nutrition research. Internationale Zeitschrift fur Vitamin- und Ernahrungsforschung. Journal international de vitaminologie et de nutrition (2024)

“ALA supplementation had no statistically significant effect on iron-related parameters.”
Key Findings:
  • In subgroup analysis, ALA significantly increased hemoglobin in patients with hematological disorders (WMD = 1.23 g/dL; 95% CI: 1.00, 1.45 g/dL; I2 = 96.6%, p < 0.001) and in studies with durations longer than 8 weeks (WMD = 1.03 g/dL; 95% CI: 0.82, 1.25 g/dL; I2 = 96.5%, p = 0.02).
  • ALA supplementation had no statistically significant effect on iron-related parameters.
  • Further research warranted to confirm findings
38
Total Studies
9.2/10
Avg Quality
11-883,627
Sample Size Range
1999-2025
Research Span

Study Type Distribution

Meta-Analysis
22
Systematic Review
8
RCT
8

This information is for educational purposes only and is not intended as medical advice. Always consult a qualified healthcare provider before starting any supplement.